FOLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amicus Therapeutics Inc (FOLD) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock shows no significant positive momentum, lacks recent positive news catalysts, and has mixed financial performance. Analysts have downgraded the stock, and there are no strong trading signals or influential figure trades to support a buy decision. It is better to hold off on this investment for now.
The technical indicators show a mixed picture. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD histogram is below 0 and negatively contracting, suggesting weak momentum. RSI is neutral at 75.618, and the stock is trading near its pivot point (14.399). There is no clear technical signal for a strong entry point.
NULL. No recent news or events suggest a positive catalyst for the stock. The financials show revenue growth, but this is offset by significant declines in net income, EPS, and gross margin.
Jefferies downgraded the stock to Hold from Buy, citing reduced expectations for a takeover. The financial performance shows a sharp decline in net income (-88.53% YoY) and EPS (-80.00% YoY). The stock also has a 40% chance of declining in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased by 23.72% YoY to $185.2M, but net income dropped by 88.53% YoY to $1.69M. EPS fell by 80% YoY to $0.01, and gross margin decreased by 4.61% to 84.64%. While revenue growth is positive, the sharp declines in profitability metrics are concerning.
Jefferies downgraded the stock to Hold from Buy with a reduced price target of $14.50 (from $16). The downgrade reflects reduced expectations for a takeover, which was previously a potential catalyst for the stock.
